Older Coverage
stories 301–360 of 633IPO
SpaceX's $1T Dream Meets Its First Insider Lockup Test
Roughly 911.5 million SpaceX shares become eligible for sale as insider lockups expire this week, a real supply test for a stock already down nearly half from its June IPO peak.
SoftBank Jumps as Asia Tech Tracks AI Rally
IPO
SoftBank Jumps as Asia Tech Tracks AI Rally
SoftBank shares surged more than 10% as Asian tech stocks tracked a strong Wall Street rally, with Arm's chip royalty optimism and gains at SK Hynix and Samsung all contributing.
SoftBank Surges 14% as Asia Tech Rallies
IPO+13.96% SoftBank
SoftBank Surges 14% as Asia Tech Rallies
SoftBank jumped nearly 14% and the KOSPI and Nikkei both rose more than 3.6% as Asian tech stocks tracked Wall Street's record-setting AI-fueled session.
Pinterest Beats Q2, Falls 8% on Soft Q3 Outlook
IPO-8.3% after hours
Pinterest Beats Q2, Falls 8% on Soft Q3 Outlook
Pinterest topped Q2 revenue and EPS estimates, but shares fell more than 8% in after-hours trading after Q3 guidance came in below what investors wanted to see.
Pinterest Beats the Quarter, Falls 7% on Guidance
IPO$1.18B Q2 revenue
Pinterest Beats the Quarter, Falls 7% on Guidance
Pinterest beat Q2 revenue and user growth estimates, but shares fell 7% after the company guided to Q3 revenue growth decelerating to 13-15% amid intensifying ad competition from Instagram.
SpaceX Beats in First Earnings Report Since IPO
IPO$7.81B Q2 revenue
SpaceX Beats in First Earnings Report Since IPO
SpaceX posted $7.81B in Q2 revenue, beating estimates by 13%, but shares swung after AI infrastructure capex hit $15.83B for the quarter, far above what analysts expected.
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
IPO$17/share IPO
Attovia Prices IPO as Biotech's Public Pipeline Fills Out
Attovia Therapeutics priced its Nasdaq IPO at $17 a share while Latigo Biotherapeutics advances its own S-1, the latest signs that the biotech listing window is filling with genuine clinical-stage pipelines.
Lucid's Turnaround Bets on $1.4B in Savings and Robotaxis
IPO$1.4B cash-savings target
Lucid's Turnaround Bets on $1.4B in Savings and Robotaxis
Lucid launched an operational reset targeting $1.4B in 2026 cash savings, leaning on its Uber- and Nuro-linked robotaxi program as one of four priorities meant to fix a widening quarterly loss.
Tesla's China Business Is Its Cash Cow and Its Risk
IPO
Tesla's China Business Is Its Cash Cow and Its Risk
Ars Technica examines how much of Tesla's profitability still runs through China, and how quickly domestic Chinese EV makers are taking the share that funds it.
Palantir Revenue Jumps 93%, Stock Surges 29%
IPO$1.94B Q2 revenue
Palantir Revenue Jumps 93%, Stock Surges 29%
Palantir posted $1.94B in Q2 revenue, raised full-year guidance to roughly $8.15B, and watched its stock climb 29% in a single session as US commercial revenue grew 149% year over year.
Latigo Sets Terms for a $272M Nasdaq IPO
IPO$272M IPO
Latigo Sets Terms for a $272M Nasdaq IPO
Latigo Biotherapeutics set terms for a $272M Nasdaq IPO under ticker LTGO, pricing 16M shares at $16-18 to fund late-stage trials of its non-opioid Nav1.8 pain drug, a rival to Vertex's Journax.
What Circle's Trading Multiple Means for Coinbase
IPO
What Circle's Trading Multiple Means for Coinbase
Circle's stock trades well below its post-IPO peak even with USDC's volume growing, and that public multiple is the most direct read available on how the market is now pricing Coinbase's own stablecoin-dependent revenue.
Robotics' IPO Pipeline: Who's Actually Ready
IPO
Robotics' IPO Pipeline: Who's Actually Ready
Figure AI at a private $39B valuation and China's Unitree pursuing a Shanghai STAR Market listing represent two very different paths to a robotics IPO -- and neither looks genuinely ready by the disclosure standards Cerebras and SpaceX have just set.
The Nuclear-Chip IPO Pipeline Nobody's Pricing In
IPO
The Nuclear-Chip IPO Pipeline Nobody's Pricing In
Valar Atomics at a $6B private valuation and OLIX at $3.3B are both explicitly infrastructure bets, not software -- and neither has a clear public comp set yet, which means whoever lists first effectively prices the entire category.
Cerebras, Three Months Public: The Scorecard
IPO
Cerebras, Three Months Public: The Scorecard
Cerebras went public in May at a $56.43B implied valuation, becoming the market's clearest test case for whether a pure-play AI chip challenger to Nvidia can hold a premium multiple once quarterly numbers replace private-market narrative.
Tech's Biotech IPO Window Is Quietly Reopening
IPO
Tech's Biotech IPO Window Is Quietly Reopening
While tech IPOs grab headlines, this week's actual new listings are almost entirely biotech -- a sign the broader IPO window is widening beyond the handful of AI mega-caps everyone's watching.
The Anthropic-OpenAI IPO Race, Scored
IPO
The Anthropic-OpenAI IPO Race, Scored
Anthropic confidentially filed for IPO first, at a $965B valuation on a $47B revenue run rate -- but OpenAI's IPO pipeline is also active, and the two companies are now effectively racing to define what an AI-lab public listing should look like.
SpaceX Reports First Earnings as a Public Company Tuesday
IPO
SpaceX Reports First Earnings as a Public Company Tuesday
SpaceX posts its first-ever quarterly results Tuesday after market close, with Wall Street modeling roughly $6.88B in revenue -- the first real test of the $1.4T valuation the market has been pricing on faith since June.
BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs
IPO$100M IPO target
BlossomHill Files for $100M Nasdaq IPO in Cancer Drugs
BlossomHill Therapeutics filed for a $100M Nasdaq IPO under ticker BLSM, adding an oncology-focused biotech with $257M in prior funding to a summer pipeline of clinical-stage listings led by J.P. Morgan, Leerink and Guggenheim.
Databricks' $188B Mark Gets a Retail-Adjacent Front Door
IPO
Databricks' $188B Mark Gets a Retail-Adjacent Front Door
Clear Street's new pre-IPO platform is opening accredited-investor access to $188B-valued Databricks through an SPV structure -- a preview of how late-stage AI names may get priced before they ever file an S-1.
Westinghouse's IPO Filing Is a Bet on AI's Power Problem
IPO
Westinghouse's IPO Filing Is a Bet on AI's Power Problem
Nuclear reactor supplier Westinghouse Electric confidentially filed for a US IPO, riding investor enthusiasm for nuclear power as Big Tech's AI datacenter buildout strains the grid.
Blue Owl-Backed Latigo Advances Nasdaq IPO Plans
IPO
Blue Owl-Backed Latigo Advances Nasdaq IPO Plans
Latigo Biotherapeutics filed an amended S-1 this week, advancing its Nasdaq IPO to fund a pivotal Phase 3 trial for its non-opioid pain drug ahead of the trial itself starting.
SpaceX's Earnings Week Is a Referendum on AI Valuations
IPO~$116B unlock
SpaceX's Earnings Week Is a Referendum on AI Valuations
SpaceX's first public earnings report and a roughly $116 billion lockup unlock land the same week the stock sits about 20% below its IPO price -- a live test of how much AI-era enthusiasm public markets will still pay for.
Coinbase's Circle Renewal Is a Preview of Crypto's IPO Math
IPO
Coinbase's Circle Renewal Is a Preview of Crypto's IPO Math
Coinbase renewing its Circle revenue-sharing deal even as trading revenue fell 19% for a third straight quarter shows crypto public companies leaning on stable, subscription-like income to offset volatile trading revenue.
Neoclouds Are Quietly Lining Up Behind SpaceX for IPOs
IPO
Neoclouds Are Quietly Lining Up Behind SpaceX for IPOs
Nscale hiring Goldman Sachs and JPMorgan for a possible late-2026 IPO, on the heels of a $14.6 billion private valuation and a $1.65 billion Anyscale acquisition, is an early look at the neocloud sector's own path toward public markets.
Consumer IPOs Are Getting Crushed While Biotech Pops
IPO
Consumer IPOs Are Getting Crushed While Biotech Pops
Jersey Mike's opened 9% below its IPO price the same day Reformation traded flat, while Apnimed popped 37.5% days later -- public investors are rewarding unmet-need biotech and discounting mature consumer brands.
The AI Lab IPO Race Is Now a Profitability Contest
IPO
The AI Lab IPO Race Is Now a Profitability Contest
With OpenAI and Anthropic both racing toward IPOs targeting valuations near $1 trillion, and OpenAI's own leadership reportedly expecting Anthropic to list first, public-market readiness increasingly hinges on profitability trajectory rather than raw scale.
Unitree's IPO Gives Humanoid Robotics a Real Price Tag
IPO
Unitree's IPO Gives Humanoid Robotics a Real Price Tag
Unitree's Shanghai IPO, with secondary-market chatter running toward $14.8 billion against a $6.2 billion base, is about to give the humanoid-robotics sector its first transparent public price -- a sharp contrast to Figure's opaque $39 billion private mark.
Why Musk's SpaceX Shares Stay Locked Until 2027
IPO
Why Musk's SpaceX Shares Stay Locked Until 2027
Elon Musk and a select group of SpaceX insiders remaining locked out of this week's share unlock until mid-2027, while other pre-IPO holders can sell, is a founder-alignment signal other AI-scale IPO candidates may want to copy.
Coinbase's Third Straight Down Quarter, With a Twist
IPO
Coinbase's Third Straight Down Quarter, With a Twist
Coinbase revenue fell 19% to $1.22B in a third consecutive quarterly decline, yet the company posted a record 10.3% share of global crypto trading volume -- shrinking revenue and growing market share at the same time.
Muted Consumer IPO Debuts Are a Warning for the Tech Pipeline
IPO
Muted Consumer IPO Debuts Are a Warning for the Tech Pipeline
Reformation and Jersey Mike's both priced and debuted within days of each other with muted first-day performance, a real-time read on risk appetite that every AI-adjacent IPO waiting in the wings should be watching closely.
Unitree's IPO Subscription Opens August 10 -- What Changed
IPO
Unitree's IPO Subscription Opens August 10 -- What Changed
Unitree set public subscription for August 10 on its Shanghai STAR Market IPO, offering 40.45 million shares, with first-half 2026 revenue guidance implying 35.6-45.4% year-over-year growth.
SpaceX Moves to Buy 130,000 Acres of Louisiana Marshland
IPO
SpaceX Moves to Buy 130,000 Acres of Louisiana Marshland
SpaceX is set to acquire roughly 130,000 acres of marshland in southern Louisiana, a major post-IPO capital deployment that lands the same week as its first public earnings report and lockup unlock.
Eric Trump-Backed Space-Eyes Bets Defense Tech on a SPAC
IPO
Eric Trump-Backed Space-Eyes Bets Defense Tech on a SPAC
Space-Eyes, a counter-drone and geospatial intelligence company backed by Eric Trump, agreeing to go public through a $638 million merger with McKinley Acquisition Corp shows blank-check listings finding real traction in defense tech, not just robotics.
A $100M SPAC IPO Signals Blank-Check Issuance Is Back
IPO
A $100M SPAC IPO Signals Blank-Check Issuance Is Back
East West Ave Acquisition Corp pricing a $100 million IPO targeting fintech, digital assets and energy deals is a small but real signal that blank-check issuance -- not just SPAC mergers -- is picking back up in 2026.
The US Just Blacklisted Foreign Humanoid Robots
IPO
The US Just Blacklisted Foreign Humanoid Robots
The US added foreign-made humanoid and quadruped robots to the FCC's national-security Covered List just days before Unitree's Shanghai IPO, effectively closing off what would otherwise be China's largest addressable robotics market.
What Unitree's Shanghai Listing Means for US Investors
IPO
What Unitree's Shanghai Listing Means for US Investors
Unitree Robotics choosing Shanghai's STAR Market over a US listing for its IPO is a clear example of how US-China tensions are pushing China's most valuable AI and robotics companies to list at home, cutting off ordinary US investors from direct access.
SpaceX's $116B Lockup Unlock Is a Bigger Test Than Earnings
IPO
SpaceX's $116B Lockup Unlock Is a Bigger Test Than Earnings
Starting August 6, up to 911.5 million SpaceX shares -- worth roughly $116B -- become eligible for sale in a staggered release, a supply event that dwarfs the stock's current public float.
Robinhood Now Makes More Money on Predictions Than Stocks
IPO
Robinhood Now Makes More Money on Predictions Than Stocks
Robinhood now generates more revenue from prediction markets than from traditional stock trading, a structural shift in its business mix that public-market investors are still working out how to price.
Biotech IPOs Are Upsizing Mid-Roadmap in 2026
IPO
Biotech IPOs Are Upsizing Mid-Roadmap in 2026
Several of 2026's biotech IPOs have expanded their target raise between initial filing and pricing, a sign the sector's strong average return this year has pulled in enough demand that bankers are re-cutting deal size on the fly.
SpaceX Leads a Genuinely Crowded Public-Markets Earnings Week
IPO
SpaceX Leads a Genuinely Crowded Public-Markets Earnings Week
SpaceX's first public earnings report anchors an unusually dense week of public-market disclosures across space, fintech and crypto, giving investors a rare same-week comparison of how differently AI-era companies are actually monetizing.
Why Robotics Is Quietly Becoming the SPAC Market's Favorite Exit
IPO
Why Robotics Is Quietly Becoming the SPAC Market's Favorite Exit
Between Agility Robotics' $2.5B SPAC merger and Michael Klein's newest blank-check vehicle, 2026's SPAC revival is being built on capital-intensive robotics and infrastructure, not the last cycle's meme stocks.
SPACs Are Quietly Having Their Best Stretch Since 2021
IPO
SPACs Are Quietly Having Their Best Stretch Since 2021
Three SPACs priced or announced deals in one week -- Churchill Capital XIII, East West Ave, and Space-Eyes' merger vehicle -- a pickup in blank-check issuance overshadowed by this week's AI mega-rounds.
The IPO Window Is Splitting Into Two Very Different Tiers
IPO
The IPO Window Is Splitting Into Two Very Different Tiers
This week's debuts split the 2026 IPO market sharply: differentiated biotech stories got double-digit pops, while mature, sponsor-backed consumer brands opened flat or down regardless of profitability.
Miami's Space-Eyes to Go Public in $638M SPAC Merger
IPO$638M
Miami's Space-Eyes to Go Public in $638M SPAC Merger
Space-Eyes, a Miami-based AI counter-drone and geospatial intelligence startup, will go public via a SPAC merger with McKinley Acquisition Corp at a $638 million equity value.
DEEP DIVE
Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill
IPO$192M IPO
Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill
Apnimed shares jumped as much as 37.5% in their Nasdaq debut after the Phase 3 biotech priced its upsized IPO at $16 a share, raising $192 million to fund what could become the first FDA-approved pill for obstructive sleep apnea.
East West Ave Prices $100M SPAC IPO on Nasdaq
IPO$100M SPAC IPO
East West Ave Prices $100M SPAC IPO on Nasdaq
East West Ave Acquisition Corp priced a $100 million IPO of 10 million units at $10 each, targeting fintech, digital assets and energy deal opportunities as blank-check listings continue picking up in 2026.
Eric Trump-Backed Space-Eyes to Go Public in $638M SPAC Deal
IPO$638M SPAC merger
Eric Trump-Backed Space-Eyes to Go Public in $638M SPAC Deal
Space-Eyes, a counter-drone and geospatial intelligence company backed by Eric Trump, agreed to go public through a merger with McKinley Acquisition Corp valuing the combined business at $638 million, with the combined company expected to list as CUAS.
Michael Klein's 13th SPAC Prices Upsized $360M IPO
IPO$360M SPAC IPO
Michael Klein's 13th SPAC Prices Upsized $360M IPO
Churchill Capital Corp XIII, Michael Klein's thirteenth blank-check company, priced an upsized $360 million IPO and began trading on Nasdaq as XIIIU, continuing a prolific run of serial SPAC issuance.
Unitree Sets Shanghai IPO Subscription Dates
IPO~$618M target
Unitree Sets Shanghai IPO Subscription Dates
Chinese humanoid maker Unitree Robotics set book-building for August 5 and public subscription for August 10 on its Shanghai STAR Market IPO, targeting roughly $618 million at a $6.2 billion base valuation.
Apnimed Prices Upsized IPO at $16, Raises $192M
IPO$192M IPO
Apnimed Prices Upsized IPO at $16, Raises $192M
Apnimed priced an upsized IPO at $16 per share, raising $192 million ahead of its Nasdaq debut under ticker APMD, betting on the first potential FDA-approved pill for obstructive sleep apnea.
Michael Klein's Churchill Capital XIII Prices $360M IPO
IPO$360M IPO
Michael Klein's Churchill Capital XIII Prices $360M IPO
Serial SPAC sponsor Michael Klein priced Churchill Capital Corp XIII's upsized IPO at $360 million, his latest blank-check vehicle as the SPAC market shows fresh signs of life in 2026.
Why 2026's IPO Debuts Are Splitting Into Two Tiers
IPO
Why 2026's IPO Debuts Are Splitting Into Two Tiers
This week's IPO calendar is splitting cleanly into two tiers -- AI-adjacent and clinical-stage biotech names popping double digits, while established consumer and franchise brands price cleanly but open flat or down, a divergence worth watching as the 2026 IPO window matures.
Reformation Debuts on NYSE, Raises $210.9M
IPO$210.9M raised
Reformation Debuts on NYSE, Raises $210.9M
Sustainable womenswear brand Reformation priced its IPO at $15 a share, raising $210.9 million and debuting on the NYSE at a roughly $886 million market value backed by private equity firm Permira.
Reformation Opens Flat in $211M NYSE Debut
IPO$886M valuation
Reformation Opens Flat in $211M NYSE Debut
Permira-backed sustainable fashion retailer Reformation raised $210.9 million in its NYSE debut, pricing at the bottom of its range and opening flat at $15 for an $886 million market value, well below its initial $1 billion target.
Jersey Mike's Falls Below IPO Price in NYSE Debut
IPO$7.3B valuation
Jersey Mike's Falls Below IPO Price in NYSE Debut
Jersey Mike's shares opened as much as 9% below their $23 IPO price on the NYSE Thursday before partially recovering, after the Blackstone-backed sandwich chain raised roughly $1 billion valuing the company at $7.3 billion.
Reformation Opens Flat, Valued at $886M in NYSE Debut
IPO$886M valuation
Reformation Opens Flat, Valued at $886M in NYSE Debut
Reformation opened flat at its $15 IPO price in its NYSE debut Thursday, valuing the Permira-backed sustainable fashion brand at $886.1 million after it raised $210.9 million pricing at the bottom of its range.
Jersey Mike's Raises $1B in Blackstone-Backed NYSE Debut
IPO$1B IPO
Jersey Mike's Raises $1B in Blackstone-Backed NYSE Debut
Jersey Mike's began trading on the NYSE under ticker JMKE after pricing its IPO at $23 a share, raising roughly $1 billion and valuing the sandwich chain at $7.3 billion, though shares opened below the IPO price as Blackstone retains majority voting control.
Neocloud Nscale Preps Investor Pitch for Multibillion IPO
IPOMultibillion IPO target
Neocloud Nscale Preps Investor Pitch for Multibillion IPO
AI neocloud Nscale is getting ready to pitch investors on a multibillion-dollar IPO, having hired Goldman Sachs and JPMorgan after raising $2 billion at a $14.6 billion valuation earlier this year.
Laser Photonics Files Fresh S-1 for Warrant Share Registration
IPO11.8M shares registered
Laser Photonics Files Fresh S-1 for Warrant Share Registration
Laser Photonics filed a new S-1 covering nearly 11.8 million warrant-linked shares for resale, the latest in a series of 2026 filings as the small-cap laser-cleaning maker manages its capital structure.